Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice

Anil Kachroo, Lianna R. Orlando, David Grandy, Jiang Fan Chen, Anne B. Young, Michael A. Schwarzschild

    Research output: Contribution to journalArticle

    116 Citations (Scopus)

    Abstract

    Evidence for heteromeric receptor complexes comprising adenosine A 2A and metabotropic glutamate 5 (mGlu5) receptors in striatum has raised the possibility of synergistic interactions between striatal A 2A and mGlu5 receptors. We investigated the role of striatal A 2A receptors in the locomotor stimulant and antiparkinsonian properties of mGlu5 antagonists using complementary pharmacologic and genetic approaches. Locomotion acutely stimulated by the mGlu5 antagonist [2-methyl-6-(phenylethynyl)-pyridine (MPEP)] was absent in mGlu5 knock-out (KO) mice and was potentiated by an A2A antagonist KW-6002 [(E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methylxanthine], both in normal and in dopamine-depleted (reserpinized) mice. Conversely, the MPEP-induced motor response was markedly attenuated in single and double A2A and D 2 receptor KO mice. In contrast, motor stimulation by a D1 dopamine agonist was not attenuated in the KO mice. The A2A receptor dependence of MPEP-induced motor stimulation was investigated further using a postnatal forebrain-specific conditional (Cre/loxP system) KO of the A 2A receptor. MPEP loses the ability to stimulate locomotion in conditional KO mice, suggesting that this mGlu5 antagonist effect requires the postdevelopmental action of striatal A2A receptors. The potentiation of mGlu5 antagonist-induced motor stimulation by an A2A antagonist and its dependence on both D2 and forebrain A2A receptors highlight the functional interdependence of these receptors. These data also strengthen a rationale for pursuing a combinational drug strategy for enhancing the antiparkinsonian effects of A2A and mGlu5 antagonists.

    Original languageEnglish (US)
    Pages (from-to)10414-10419
    Number of pages6
    JournalJournal of Neuroscience
    Volume25
    Issue number45
    DOIs
    StatePublished - Nov 9 2005

    Fingerprint

    Adenosine A2A Receptors
    Excitatory Amino Acid Antagonists
    Glutamic Acid
    Corpus Striatum
    Knockout Mice
    Metabotropic Glutamate 5 Receptor
    Antiparkinson Agents
    Locomotion
    Prosencephalon
    Dopamine Agonists
    Adenosine
    Dopamine
    Pharmaceutical Preparations
    pyridine

    Keywords

    • Adenosine
    • G-protein-coupled receptor
    • Knock-out
    • Locomotion
    • Metabotropic
    • Parkinson's disease

    ASJC Scopus subject areas

    • Neuroscience(all)

    Cite this

    Kachroo, A., Orlando, L. R., Grandy, D., Chen, J. F., Young, A. B., & Schwarzschild, M. A. (2005). Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. Journal of Neuroscience, 25(45), 10414-10419. https://doi.org/10.1523/JNEUROSCI.3660-05.2005

    Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. / Kachroo, Anil; Orlando, Lianna R.; Grandy, David; Chen, Jiang Fan; Young, Anne B.; Schwarzschild, Michael A.

    In: Journal of Neuroscience, Vol. 25, No. 45, 09.11.2005, p. 10414-10419.

    Research output: Contribution to journalArticle

    Kachroo, A, Orlando, LR, Grandy, D, Chen, JF, Young, AB & Schwarzschild, MA 2005, 'Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice', Journal of Neuroscience, vol. 25, no. 45, pp. 10414-10419. https://doi.org/10.1523/JNEUROSCI.3660-05.2005
    Kachroo, Anil ; Orlando, Lianna R. ; Grandy, David ; Chen, Jiang Fan ; Young, Anne B. ; Schwarzschild, Michael A. / Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. In: Journal of Neuroscience. 2005 ; Vol. 25, No. 45. pp. 10414-10419.
    @article{87073f5a3715499a88286db0184fcd1f,
    title = "Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice",
    abstract = "Evidence for heteromeric receptor complexes comprising adenosine A 2A and metabotropic glutamate 5 (mGlu5) receptors in striatum has raised the possibility of synergistic interactions between striatal A 2A and mGlu5 receptors. We investigated the role of striatal A 2A receptors in the locomotor stimulant and antiparkinsonian properties of mGlu5 antagonists using complementary pharmacologic and genetic approaches. Locomotion acutely stimulated by the mGlu5 antagonist [2-methyl-6-(phenylethynyl)-pyridine (MPEP)] was absent in mGlu5 knock-out (KO) mice and was potentiated by an A2A antagonist KW-6002 [(E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methylxanthine], both in normal and in dopamine-depleted (reserpinized) mice. Conversely, the MPEP-induced motor response was markedly attenuated in single and double A2A and D 2 receptor KO mice. In contrast, motor stimulation by a D1 dopamine agonist was not attenuated in the KO mice. The A2A receptor dependence of MPEP-induced motor stimulation was investigated further using a postnatal forebrain-specific conditional (Cre/loxP system) KO of the A 2A receptor. MPEP loses the ability to stimulate locomotion in conditional KO mice, suggesting that this mGlu5 antagonist effect requires the postdevelopmental action of striatal A2A receptors. The potentiation of mGlu5 antagonist-induced motor stimulation by an A2A antagonist and its dependence on both D2 and forebrain A2A receptors highlight the functional interdependence of these receptors. These data also strengthen a rationale for pursuing a combinational drug strategy for enhancing the antiparkinsonian effects of A2A and mGlu5 antagonists.",
    keywords = "Adenosine, G-protein-coupled receptor, Knock-out, Locomotion, Metabotropic, Parkinson's disease",
    author = "Anil Kachroo and Orlando, {Lianna R.} and David Grandy and Chen, {Jiang Fan} and Young, {Anne B.} and Schwarzschild, {Michael A.}",
    year = "2005",
    month = "11",
    day = "9",
    doi = "10.1523/JNEUROSCI.3660-05.2005",
    language = "English (US)",
    volume = "25",
    pages = "10414--10419",
    journal = "Journal of Neuroscience",
    issn = "0270-6474",
    publisher = "Society for Neuroscience",
    number = "45",

    }

    TY - JOUR

    T1 - Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice

    AU - Kachroo, Anil

    AU - Orlando, Lianna R.

    AU - Grandy, David

    AU - Chen, Jiang Fan

    AU - Young, Anne B.

    AU - Schwarzschild, Michael A.

    PY - 2005/11/9

    Y1 - 2005/11/9

    N2 - Evidence for heteromeric receptor complexes comprising adenosine A 2A and metabotropic glutamate 5 (mGlu5) receptors in striatum has raised the possibility of synergistic interactions between striatal A 2A and mGlu5 receptors. We investigated the role of striatal A 2A receptors in the locomotor stimulant and antiparkinsonian properties of mGlu5 antagonists using complementary pharmacologic and genetic approaches. Locomotion acutely stimulated by the mGlu5 antagonist [2-methyl-6-(phenylethynyl)-pyridine (MPEP)] was absent in mGlu5 knock-out (KO) mice and was potentiated by an A2A antagonist KW-6002 [(E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methylxanthine], both in normal and in dopamine-depleted (reserpinized) mice. Conversely, the MPEP-induced motor response was markedly attenuated in single and double A2A and D 2 receptor KO mice. In contrast, motor stimulation by a D1 dopamine agonist was not attenuated in the KO mice. The A2A receptor dependence of MPEP-induced motor stimulation was investigated further using a postnatal forebrain-specific conditional (Cre/loxP system) KO of the A 2A receptor. MPEP loses the ability to stimulate locomotion in conditional KO mice, suggesting that this mGlu5 antagonist effect requires the postdevelopmental action of striatal A2A receptors. The potentiation of mGlu5 antagonist-induced motor stimulation by an A2A antagonist and its dependence on both D2 and forebrain A2A receptors highlight the functional interdependence of these receptors. These data also strengthen a rationale for pursuing a combinational drug strategy for enhancing the antiparkinsonian effects of A2A and mGlu5 antagonists.

    AB - Evidence for heteromeric receptor complexes comprising adenosine A 2A and metabotropic glutamate 5 (mGlu5) receptors in striatum has raised the possibility of synergistic interactions between striatal A 2A and mGlu5 receptors. We investigated the role of striatal A 2A receptors in the locomotor stimulant and antiparkinsonian properties of mGlu5 antagonists using complementary pharmacologic and genetic approaches. Locomotion acutely stimulated by the mGlu5 antagonist [2-methyl-6-(phenylethynyl)-pyridine (MPEP)] was absent in mGlu5 knock-out (KO) mice and was potentiated by an A2A antagonist KW-6002 [(E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methylxanthine], both in normal and in dopamine-depleted (reserpinized) mice. Conversely, the MPEP-induced motor response was markedly attenuated in single and double A2A and D 2 receptor KO mice. In contrast, motor stimulation by a D1 dopamine agonist was not attenuated in the KO mice. The A2A receptor dependence of MPEP-induced motor stimulation was investigated further using a postnatal forebrain-specific conditional (Cre/loxP system) KO of the A 2A receptor. MPEP loses the ability to stimulate locomotion in conditional KO mice, suggesting that this mGlu5 antagonist effect requires the postdevelopmental action of striatal A2A receptors. The potentiation of mGlu5 antagonist-induced motor stimulation by an A2A antagonist and its dependence on both D2 and forebrain A2A receptors highlight the functional interdependence of these receptors. These data also strengthen a rationale for pursuing a combinational drug strategy for enhancing the antiparkinsonian effects of A2A and mGlu5 antagonists.

    KW - Adenosine

    KW - G-protein-coupled receptor

    KW - Knock-out

    KW - Locomotion

    KW - Metabotropic

    KW - Parkinson's disease

    UR - http://www.scopus.com/inward/record.url?scp=27744450594&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=27744450594&partnerID=8YFLogxK

    U2 - 10.1523/JNEUROSCI.3660-05.2005

    DO - 10.1523/JNEUROSCI.3660-05.2005

    M3 - Article

    C2 - 16280580

    AN - SCOPUS:27744450594

    VL - 25

    SP - 10414

    EP - 10419

    JO - Journal of Neuroscience

    JF - Journal of Neuroscience

    SN - 0270-6474

    IS - 45

    ER -